For the quarter ending 2025-12-31, AYTU made $15,165K in revenue. -$10,584K in net income. Net profit margin of -69.79%.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Net revenue | 15,165 | 13,888 | 15,678 | 18,452 |
| Cost of goods sold | 5,541 | 4,702 | 5,158 | 5,646 |
| Gross profit | 9,624 | 9,186 | 10,520 | 12,806 |
| Selling and marketing | 5,998 | 5,322 | 5,027 | 5,194 |
| General and administrative | 5,070 | 4,924 | 4,073 | 4,109 |
| Research and development | 0 | 0 | 369 | 162 |
| Amortization of intangible assets | 526 | 444 | 921 | 920 |
| Restructuring costs | 0 | 0 | 439 | - |
| Impairment expense | - | - | 4,351 | - |
| Total operating expenses | 11,594 | 10,690 | 15,179 | 10,385 |
| Loss from operations | -1,970 | -1,504 | -4,659 | 2,421 |
| Other income, net | 190 | 201 | -545 | 36 |
| Interest expense | 560 | 516 | 905 | 900 |
| Derivative warrant liabilities (loss) gain | -8,244 | 3,784 | -3,422 | 2,261 |
| Loss on extinguishment of debt | - | - | 0 | - |
| (loss) income from continuing operations before income tax expense | -10,584 | 1,965 | -9,530 | 3,818 |
| Income tax benefit (expense) | 0 | 0 | 77 | -122 |
| Net (loss) income from continuing operations | -10,584 | 1,965 | -9,607 | 3,940 |
| Net income from discontinued operations, net of tax | 0 | 0 | 189 | 54 |
| Net (loss) income | -10,584 | 1,965 | -9,515 | 3,994 |
| Basic - net (loss) income (in dollars per share) | -1.05 | 0.21 | -1.525 | 0.65 |
| Basic weighted-average common shares outstanding (note 17) (in shares) | 10,036,359 | 9,441,073 | -2,961,454.5 | 6,134,634 |
| Diluted - net loss (in dollars per share) | -1.05 | -0.08 | - | 0.21 |
| Diluted weighted-average common shares outstanding (note 17) (in shares) | 10,036,359 | 19,476,635 | - | 8,204,453 |
AYTU BIOPHARMA, INC (AYTU)
AYTU BIOPHARMA, INC (AYTU)